IP Library Granted Patent US 9,266,946
Granted Patent B2
US 9,266,946 · App. 14/251,932 · Granted Feb 23, 2016

Targeting ABCB5 for cancer therapy

Inventors: Markus H. Frank (Cambridge, MA); Natasha Y. Frank (Cambridge, MA); Mohamed H. Sayegh (Westwood, MA)
Assignee: The Brigham and Women's Hospital, Inc.
C07K16/18A61K2039/505C07K2317/56C07K2317/565C07K2317/732C07K2317/734
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,266,946
App. No.
14/251,932
Granted
Feb 23, 2016
Kind
B2
Abstract

The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof.

Claims (14)

1. A method for treating a subject, comprising

systemically administering an isolated antibody that selectively binds to ABCB5 to a subject having cancer in an effective amount to treat the cancer, wherein the isolated antibody is not co-administered with a chemotherapeutic agent.

2. The method of claim 1 , wherein the isolated antibody is a monoclonal antibody.

3. The method of claim 1 , wherein the isolated antibody has at least one human region.

4. The method of claim 1 , wherein the isolated antibody competitively inhibits binding of mAb 3C2-1D12 to ABCB5.

5. The method of claim 1 , wherein the isolated antibody is of immunoglobulin class IgA, IgGb 1, IgG2, IgG3, IgG4 or IgM.

6. The method of claim 1 , wherein the isolated antibody is a single chain antibody.

7. The method of claim 1 , wherein the subject has melanoma.

8. The method of claim 1 , wherein the subject is a human subject.

9. The method of claim 1 , wherein the subject is a companion animal.

10. The method of claim 1 , wherein the cancer is a cancer having cancer stem cells that express ABCB5 and is selected from the group consisting of biliary tract cancer; brain cancer; breast cancer; cervical cancer; choriocarcinoma; colon cancer; endometrial cancer; esophageal cancer; gastric cancer; intraepithelial neoplasms; lymphomas; liver cancer; lung cancer (e.g. small cell and non-small cell); neuroblastomas; oral cancer; ovarian cancer; pancreas cancer; prostate cancer; rectal cancer; sarcomas; skin cancer; testicular cancer; thyroid cancer; and renal cancer.

11. The method of claim 1 , further comprising, prior to the treatment of the subject detecting the presence of ABCB5 positive stem cells.

12. The method of claim 11 , wherein the presence of ABCB5 positive stem cells is detected by contacting a sample from a subject with a peptide that selectively binds to ABCB5 in order to detect cells that bind to the peptide.

13. The method of claim 12 , wherein the sample is a sample of a tumor mass.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2014
From: FRANK, MARKUS H.; FRANK, NATASHA; SAYEGH, MOHAMED H.
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 032868/0776 →
Continuity (5)
Continuation 13044854 · Mar 10, 2011
Division 12101428 · Apr 11, 2008
Provisional Application 61007059 · Dec 11, 2007
Provisional Application 60923128 · Apr 12, 2007
Related Publication 20140302031A1 · Oct 9, 2014